Hoth Therapeutics, Inc. to Begin Pilot Study at Massachusetts General Hospital Vaccine and Immunotherapy Center

NEW YORK, March 4, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that it will begin its Pilot Study of BioLexa application on diabetic skin ulcers.  

Module 1 of Hoth's Pilot Study will establish whether the BioLexa platform has pro-healing properties in the context of chronic diabetic ulcers, with and without substantial bacterial burden.  This study will be performed under a Scientific Research Agreement with Massachusetts General Hospital Vaccine and Immunotherapy Center ("MGH").  Hoth has provided the MGH team with its first delivery of the therapeutic compound (BioLexa) which will be applied in a murine model.

Robb Knie, CEO of Hoth Therapeutics, commented, "We look forward to this study at MGH.  Our goal is to expand the BioLexa platform to the areas of dermatology and chronic wound care and believe that the development of effective treatments for diabetic ulcers is a key area in which BioLexa may provide major relief to patients in need."  Dr. Andrew Herr, Hoth Scientific Advisory Board member, pointed out that "diabetic skin ulcers, which affect approximately 10 million people per year in the US alone, are frequently infected by Staphylococcus aureus and other bacteria, leading to serious complications.  There is a real need for therapeutic approaches that can clear recurrent infections in diabetic skin ulcers and promote the wound healing process."

About Hoth Therapeutics, Inc.

Hoth Therapeutics Inc., a Nevada corporation, is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform. Hoth intends to use the BioLexa Platform to develop two different topical cream products: (i) a product to treat eczema and (ii) a product that reduces post-procedure infections, accelerates healing and improves clinical outcomes for patients undergoing aesthetic dermatology procedures. Hoth's initial focus will be on the development of the BioLexa Platform for the treatment of eczema.  Eczema is a disease that results in inflammation of the skin and is characterized by rash, red skin, and itchiness. Eczema is also referred to as atopic dermatitis.

Forward Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations Contact:
Phone: (646) 756-2997
Email: [email protected]
www.hoththerapeutics.com

SOURCE Hoth Therapeutics Inc.

Related Links

http://www.hoththerapeutics.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED